RE:RE:RE:VCTX210The immuno suppression is being done at a macro level on the device. My guess is that it won't work out very well, if at all. Viacyte likely knew this too and probably sold themselves to Vertex prior to starting that trial so they could cash out. Vertex is working with CRISPR on gene edited cells but that is still in preclinical stage. Not to mention their cells are embryonic which pose all kinds of other problems. If Sernova play their cards right, they could easily win this race. They just need to prove to investors they can secure the cash they need to see it through.